PALO ALTO, Calif.--(BUSINESS WIRE)--FidoCure, a leader in AI-driven precision oncology for dogs, is excited to share landmark findings on canine splenic hemangiosarcoma at the 2024 Veterinary Cancer Society (VCS) Annual Conference. This research advances the fight against the most prevalent and deadly canine cancer.
The VCS Conference, the largest and most prestigious event in veterinary oncology with over 1,400 attendees, showcases advancements in animal cancer treatment and research.
"We are honored to present our latest findings at the VCS Annual Conference," said Christina Lopes, CEO of FidoCure. "This study represents a significant leap in our understanding of canine splenic hemangiosarcoma. As patient-centric advocates who are also pet parents, we are dedicated to continuously turning science discoveries into accessible products that positively impact the last mile of cancer care—both in the clinic and at home.”
Canine splenic hemangiosarcoma, an aggressive cancer originating in the spleen, causes approximately 300,000 dog deaths annually in the U.S.
The research, led by FidoCure’s Head of Veterinary Research, Lucas Rodrigues, in collaboration with Professor James Zou, a foremost researcher in AI for canine oncology at Stanford University, involved compiling and analyzing the largest hemangiosarcoma dataset in the world, comprising millions of critical biological data points. Key findings include:
- Enhanced survival rates for dogs treated with chemotherapy or targeted therapy compared to splenectomy alone
- Identification of specific genetic mutations linked to prognosis
- Promising benefits of analyzing genomics to guide the use of small molecule therapies
"Our findings show comparable or better outcomes than standard adjuvant chemotherapy, showcasing the power of AI-driven precision oncology for dogs facing cancer. We’re proud to partner with veterinary oncologists, providing them with cutting-edge tools and insights to enhance patient care," said Rodrigues.
FidoCure is ushering in the future of biomedical products through its global patent programs, providing beloved pets with care akin to that of their two-legged family members. While this research directly combats canine hemangiosarcoma, the findings also contribute to understanding human angiosarcoma, addressing cancer on both ends of the leash.
ABOUT FIDOCURE BY THE ONE HEALTH COMPANY
FidoCure is an AI-driven precision oncology company that is transforming cancer care for dogs. FidoCure has created the world’s largest canine cancer dataset, with over 2 billion data points collected from patients treated in its network of 1,350 veterinary clinics. Learn more at www.fidocure.com.
